Late-breaking data for retatrutide, CagriSema, survodutide, and oral elecoglipron are poised to reshape near-term formulary strategy and utilization management for obesity and metabolic disease.
Look out for PyroFuZA. Those eight letters have the potential to make best use of South Africa’s natural resources and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results